ClinicalTrials.gg
RecruitingNCT07070778Updated Nov 17, 2026

Arterial Stiffness in Individuals With Breast Cancer

An interventional study of Upper Extremity Aerobic Exercise Training Program in Aerobic Exercise, Breast Cancer and Arterial Stiffness, sponsored by Hacettepe University. Recruiting at 1 site in Turkey (Türkiye). Open to female participants aged 40 Years to 69 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Hacettepe University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.
Updated Nov 17, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
40 Years to 69 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 16 studies in Breast Neoplasms by Hacettepe University — 4 open to participants now, 4 under way, none of them phase 3. Breast Neoplasms · Hacettepe University.

Planned enrollment
10th of 10
18 · median 45
Started
2025
with 3 others
No phase
10 of 16
4 open now
Registered
13th of 16
by date

Among the 16 studies in Breast Neoplasms by Hacettepe University, this one is the 10th largest by planned enrollment of the 10 interventional ones that give a count, is one of 4 that started in 2025, is one of 10 with no phase, and was the 13th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

4 of the 16 studies in Breast Neoplasms by Hacettepe University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 40 Years to 69 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Breast Neoplasms by Hacettepe University, or all of them as a file.
02

Study summary

The aim of this study was to evaluate vascular toxicity induced by anthracyclines and other anticancer drugs and to measure arterial stiffness in women with breast cancer and, in addition, to evaluate the acute and chronic arterial stiffness responses of upper extremity aerobic exercise training.

Read the detailed description

Breast cancer is the most common type of cancer in women both in the world and in our country. Today, with the technological developments, breast cancer treatments have improved considerably and the mortality rate has decreased. However, despite the developments in treatments, the quality of life of patients has still not reached the desired level. Upper extremity dysfunctions are frequently observed in patients after breast cancer treatment. This upper extremity dysfunction causes a decrease in the quality of daily life of patients. Arterial stiffness contributes to hypertension and increases the risk of cardiovascular disease. The American College of Sports Medicine (ACSM) recommends that healthy adults perform moderate to vigorous intensity aerobic exercise at least 5 times per week and resistance exercise 2-3 times per week. Aerobic exercise can reduce arterial stiffness after both acute and chronic interventions. A small number of studies on aerobic exercise have reported that this exercise training improves the functional level of patients after breast cancer. However, the effect of aerobic exercise training on arm exercise capacity and arterial stiffness in patients with breast cancer is still unclear. Thus, the results of this study may guide physiotherapists working in this field about upper extremity exercise training after breast cancer.

03

Conditions studied

  • Aerobic Exercise
  • Breast Cancer
  • Arterial Stiffness

Browse trials for

Keywords

  • breast cancer
  • Aerobic exercise training
  • Arterial Stiffness
04

Who can participate

Ages eligible
40 Years to 69 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • To be between the ages of 40-69,
  • Baseline (LVEF) >50%,
  • Absence of coronary artery disease and haemodynamically significant valvular heart disease,
  • Absence of carotid atherosclerotic plaques,
  • Volunteering to participate in the research,
  • At least 15 months after breast cancer surgery,
  • No problems in reading and/or understanding the scales and being able to co-operate with the tests.
  • Physically inactive (60 minutes of structured exercise per week \<).

Exclusion criteria

Exclusion Criteria:

  • Presence of active infection,
  • Presence of bilateral breast cancer,
  • History of surgical, neurological or orthopaedic problems that may affect upper extremity functionality other than breast cancer surgery,
  • Having a neurological disease or other clinical diagnosis that may affect cognitive status,
  • Left ventricular dysfunction and severe liver and kidney dysfunction before starting chemotherapy
  • Musculoskeletal and neurological disease that may affect exercise performance, symptomatic heart disease, previous lung surgery and malignant disease.
  • Presence of unstable hypertension or diabetes mellitus.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Other
    Upper Extremity Aerobic Exercise

    Participants will only receive a 12-week upper extremity aerobic exercise training program.

    Other: Upper Extremity Aerobic Exercise Training Program

Interventions

  • OtherUpper Extremity Aerobic Exercise Training Program

    12 weeks of supervised upper limb aerobic exercise training, 3 sessions per week, 25 minutes per session.

06

What researchers measure

Primary outcomes

  1. Arterial Stiffness

    Arterial stiffness will be assessed noninvasively using the pulse wave velocity (PWV) technique with the Mobil-O-GRAPH (TG) (I.E.M., Stolberg, Germany), an oscillometer-based device. Pulse wave velocity, augmentation pressure, reflection magnitude, agumentation index parameters will be recorded.

    Time frame: one years

Secondary outcomes

  1. Comorbidity Assessment

    The Charlson Comorbidity Index According to this index developed by the Institute of Medicine, comorbid diseases are assessed according to their severity. is scored. Comorbidities are scored from mild disease state to severe disease state. are given a score of 1, 2, 3, 4, respectively, and the score obtained by summing the scores of comorbid diseases The severity of comorbidity is also calculated according to the weighted score. One point for every ten years over the age of forty (50-59: 1 point, 60-69: 2 points, etc.)

    Time frame: one year

  2. Maximal Arm Exercise Capacity

    VO2peak requirement during arm ergometry will be estimated using MET levels calculated at each power output based on gender at various body weights and will be displayed in ml/kg/min (1 MET = 3.5 ml/kg/min)

    Time frame: one year

  3. Cardiovascular Disease Risk Scoring

    To be evaluated with SCORE2. The risk calculated according to the SCORE system is accepted as low risk if \<1%, medium risk if 1-4%, high risk if 5-9%, and very high risk if 10% and above (16). According to the SCORE2 system, \<2.5% is considered low-moderate risk, 2.5%-7.5% is considered high risk, and 7.5% and above is considered very high risk in patients aged \<50 years. In those over 50 years of age, \<5% is considered low-moderate risk, 5-10% is considered high risk, and 10% and above is considered very high risk.

    Time frame: one year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Mar 2027, 19 months after the start.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 19 months is below that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: primary completion Nov 2026 → Mar 2027 and completion Dec 2026 → Mar 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2025
First posted
Jul 17, 2025
StartActual
Jul 8, 2025
Primary completionEst.
Mar 1, 2027was Nov 2026
CompletionEst.
Mar 1, 2027was Dec 2026
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Nov 1, 2026→Mar 1, 2027
Nov 17, 2026
Study completion
Dec 1, 2026→Mar 1, 2027
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Primary completion Nov 1, 2026→Mar 1, 2027
    Study completion Dec 1, 2026→Mar 1, 2027
    + 1 other change: responsible party

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07070778
Responsible party
Ebru Calik (Professor, Hacettepe University) — Principal investigator
First posted
Jul 17, 2025
Start date
Jul 8, 2025
Primary completion
Mar 1, 2027 (estimated)
Completion
Mar 1, 2027 (estimated)
Last update
Nov 17, 2026

Study contacts

Ebru Calik Kutukcu, PhD
Contact
ebru.calik@hacettepe.edu.tr
+903123051576 ext. 195
Naciye Vardar-Yagli, PhD
Contact
naciyevardar@yahoo.com
+03123051576 ext. 129
Melda Saglam, PhD
study chair · Hacettepe University
Ebru Calik Kutukcu, PhD
study director · Hacettepe University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion